<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02909933</url>
  </required_header>
  <id_info>
    <org_study_id>COMBO - LIRA 3</org_study_id>
    <nct_id>NCT02909933</nct_id>
  </id_info>
  <brief_title>Low Dose Liraglutide and Metformin vs. High Dose Liraglutide Alone in Treatment of Obesity</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Centre Ljubljana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Centre Ljubljana</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Weight reduction is the most important treatment target when polycystic ovary syndrome (PCOS)
      is linked to obesity. Liraglutide (LIRA) in dose of 3 mg was recently approved as an
      anti-obesity drug. Metformin could enhance weight lowering potential of liraglutide.

      We investigates short term interventions with low dose liraglutide in combination with
      metformin and high dose liraglutide alone influence on significant weight reduction in obese
      women with PCOS.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The main outcome was change in body weight.</measure>
    <time_frame>Patient's body weight was measured at the base point and after 12 weeks of clinical trial.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary outcome was change in body mass index (BMI)</measure>
    <time_frame>Patient's body weight were measured at the base point and after 12 weeks of clinical trial. Patient's height was measured at the base point.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>liraglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>liraglutide 3 mg QD for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>metformin and liraglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>metformin 1000 mg BID and liraglutide 1.2 mg QD for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <arm_group_label>liraglutide</arm_group_label>
    <other_name>Victoza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin and liraglutide</intervention_name>
    <arm_group_label>metformin and liraglutide</arm_group_label>
    <other_name>Glucophage and Victoza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years old to menopause

          -  polycystic ovary syndrome (NICHD criteria)

          -  BMI of 30 kg/mÂ² or higher

        Exclusion Criteria:

          -  type 1 or type 2 diabetes mellitus

          -  history of carcinoma

          -  Cushing's syndrome or congenital (non-classic) adrenal hyperplasia

          -  personal or family history of MEN 2

          -  significant cardiovascular, kidney or hepatic disease

          -  the use of medications known or suspected to affect reproductive or metabolic
             functions

          -  the use of statins, within 90 days prior to study entry
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrej Janez, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Centre Ljubljana</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2016</study_first_submitted>
  <study_first_submitted_qc>September 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2016</study_first_posted>
  <last_update_submitted>September 16, 2016</last_update_submitted>
  <last_update_submitted_qc>September 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Centre Ljubljana</investigator_affiliation>
    <investigator_full_name>Andrej Janez</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

